Published in Adv Exp Med Biol on January 01, 2013
Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat Chem Biol (2016) 1.41
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest (2015) 1.08
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open (2013) 1.02
Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol (2014) 0.94
C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol (2013) 0.92
Applying complement therapeutics to rare diseases. Clin Immunol (2015) 0.87
Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection. PLoS Pathog (2014) 0.86
Polyphosphate suppresses complement via the terminal pathway. Blood (2013) 0.85
Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol (2015) 0.85
Blood consult: paroxysmal nocturnal hemoglobinuria and its complications. Blood (2013) 0.83
Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol (2015) 0.80
From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology (2016) 0.80
Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature. Clin Case Rep (2014) 0.79
Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma. Int Immunopharmacol (2014) 0.78
Mononuclear cells from a rare blood donor, after freezing under good manufacturing practice conditions, generate red blood cells that recapitulate the rare blood phenotype. Transfusion (2013) 0.75
The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome. BMJ Case Rep (2014) 0.75